Section Review Cardiovascular & Renal: Bradykinin degradation: potential pathways for cardiovascular therapeutic use

References

• REGOLI D, BARABE J: Pharmacology of bradykinin andrelated kinins. Pharmacol. Rev. (1980) 32:1–46.
   PubMed Web of Science ®Google Scholar
• BHOOLA KD, FIGUEROA CD, WORTHY K: Bioregulation •of kinins: kallikreins, kininogens and kininases. Phar-macol. Rev. (1992) 44:1-80. A recent, comprehensive review of kinin regulation.
   Google Scholar
• PROUD D: Kinin formation: mechanism and role ininflammatory disorders. Ann. Rev. Immunol. (1988) 6:49–83.
   PubMed Web of Science ®Google Scholar
• HALL JM: Bradykinin receptors: pharmacological prop-erties and biologic roles. Pharmacol. Ther. (1992) 56:131–190.
   PubMed Web of Science ®Google Scholar
• REGOLI D: Kinins. Br. Med. Bull. (1987) 43:270–284.
   Web of Science ®Google Scholar
• URA N, CARRE'FERO OA, ERDOS EG: Role of renal en-dopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Mt. (1987) 32:507–513.
   Google Scholar
• ORLOWSKI M, MICHAUD C, CHU TG: A soluble metalloen-dopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Ear." Biochem. (1983) 135:81–88.
   Google Scholar
• CHU TG, ORLOWSKI M: Soluble metalloendopeptidase from rat brain: action on enkephalin-containing pep-tides and other bioactive peptides. Endocrinology (1985) 116:1418–1425.
   PubMed Web of Science ®Google Scholar
• ZACEST R, °PARR S, TALAMO RC: Studies of plasmabradykinins using radiolabeled substrates. Aust. J. Exp. Biol. Med. Sci. (1974) 52:601–606.
   PubMedGoogle Scholar
• ERDOS EG: Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension (1990) 16:363–370.
   PubMed Web of Science ®Google Scholar
• ROQUES BP, NOBLE F, DAUGE V, FOURNLE-ZALUSKI M-C, BEAUMONT A: Neutral endopeptidase 24.11: structure, Inhibition, and experimental and clinical pharmacol-ogy. Pharmacol. Rev. (1993) 45:87–144.
   Google Scholar
• SCHRLEFER JA, BROUDY EP, HASSEN AH: Endopeptidase Inhibitors decrease myocardial ischaemia/reperfusion injury in an in vivo rabbit modeL J. Pharmacol. Exp. Ther. (1996) 278:1034–1039.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, CHAPPELL MC, BROSNIHAN KB, FER-RARI° CM: In vivo metabolism of angiotensin I by neutral endopeptldase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension (1992) 19:692–696.
   Google Scholar
• SCHILERO GJ, ALMENOFF P, CARDOZO C, LESSER M: Effects of peptidase inhibitors on bradykinin-induced bronchoconstriction in the rat. Peptides (1994) 8:1445–1449.
   Google Scholar
• SCHILERO GJ, ALMENOFF P, LESSER M, CARDOZO C: Peptidase inhibitors potentiate lysylbradykinin-in-duced bronchoconstriction in the rat. Regulat. Pept. (1996) 62:41–45.
   PubMed Web of Science ®Google Scholar
• GENDEN EM, MOLINEAUX CJ: Inhibition of endopepti-dase-24.15 decreases blood pressure in normotensive rats. Hypertension (1991) 18:360–365.
   PubMed Web of Science ®Google Scholar
• TISLJAR U: Thimet oligopeptidase - a review of a thiol dependent metallo-endopeptidase also known as Pz-peptidase endopeptidase 24.15 and endo-oligopepti-dase. Biol. Chem. Hoppe-Seyler (1993) 374:91–100.
   PubMed Web of Science ®Google Scholar
• SIMMONS W11, ORAWSKI AT: Membrane-bound ami-nopeptidase P from bovine lung. J. Biol. Chem. (1992) 267:4897–4903.
   PubMedGoogle Scholar
• ORAWSKI AT, SIMMONS WH: Purification and properties of membrane-bound aminopeptidase P from rat lung. Biochemistry (1995) 34:11227–11236.
   PubMed Web of Science ®Google Scholar
• CHEN X, ORFANOS SE, RYAN JW et al.: Species variation in pulmonary endothelial aminopeptidase P activity. J. Pharmacol. Exp. Ther. (1991) 269:1301–1307.
   Google Scholar
• VANHOOF G, DE MEESTER I, VAN SANDE M, SCHARPE S, YARON A: Distribution of proline-specific aminopepti-dases in human tissues and body fluids. Eur. J. din. Chem. Clin. Biochem. (1992) 30:333–338.
   PubMedGoogle Scholar
• HOLTZMAN EJ, PILLAY G, ROSENTHAL T, TARON A: Ami-nopeptidase P activity in rat organs and human serum. Anal. Biochem. (1987) 162:476–484.
   PubMed Web of Science ®Google Scholar
• MENTLEIN R, ROOST: Proteases involved in the metabo-lism of angiotensin 11, bradykinin, calcitonin gene-re-lated peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides (1996) 17709–720.
   Google Scholar
• WILKENS MR, UNWIN RJ, KENNY AJ: Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for ede-matous disorders and hypertension. Kid. Mt. (1993) 43:273–285.
   Google Scholar
• GAVRAS H: The place of anglotensin-converting enzyme •inhibitors in the treatment of cardiovascular diseases. New Engl. J. Med. (1988) 319:1541-1543. Review of clinical use of ACE inhibitors.
   Google Scholar
• WAEBER B, NUSSBERGER J, BRUNNER H: Angiotensin converting enzyme inhibitors in hypertension. In: Hy-pertension: Pathopbysiology, Diagnosis and Management. Volume 2. Laragh J11, Brenner BM (Eds.), Raven Press, New York (1990):2209–2232.
   Google Scholar
• UNGER T, GOHLKE P, GRABER MG: Converting enzyme Inhibitors. In: Pharmacology of Antihypertensive Therapeu-tics. Handbook of Experimental Pharmacology. Volume 93. Ganten D, Mulrow PJ (Eds.), Springer-Verlag, Berlin (1990):377–481.
   Google Scholar
• HARTMAN JC: The role of bradykinin and nitric oxide ••in the cardioprotective action of ACE inhibitors. Ann.Thorac. Sup, (1995) 60:789-792. Review of evidence implicating inhibition of BK metabolism in ACE-mediated cardioprotection.
   Google Scholar
• LINZ W, WIEMER G, GOHL10E P, UNGER T, SCHOLICENS .•BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharma-col. Rev. (1995) 47:25-49. Review of evidence implicating inhibition of BK metabolism in ACE-mediated cardioprotection.
   Google Scholar
• REMME WJ, LOOK MP, BOOTSMA M et al.: Neurohtunoral activation during acute myocardial ischaemia. Effect of ACE inhibition. Eur. HeartJ. (1990) 11:162–171.
   PubMed Web of Science ®Google Scholar
• LINZ W, 'WIEMER G, SCHOLICENS BA: ACE-inhibition Induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J. Mol. Cell. Cardiol. (1992) 24:909–919.
   PubMed Web of Science ®Google Scholar
• LUI X, ENGELMAN RM, ROUSOU JA, CORDIS GA, DAS DK: Attenuation of myocardial reperfusion injury by sulf-hydryl-containing angiotensin converting enzyme Cardiovasc. Drugs Ther. (1992) 6:437–443.
   Google Scholar
• HARTMAN JC, HULLINGER TG, WALL TM, SHEBUSKI RJ: Reduction of myocardial infarct size by ramiprilat is Independent of angiotensin II synthesis inhibition. Eur. J. Pharmacol. (1993) 234:229–236.
   PubMed Web of Science ®Google Scholar
• JUGGI JS, KOENIG-BERARD E, VAN GILST WH: Cardiopro-tection by angiotensin-converting enzyme inhibitors. Can. J. Cardiol. (1993) 9:336–352.
   PubMed Web of Science ®Google Scholar
• THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute infarction. Lancet (1993) 342:821–828.
   PubMed Web of Science ®Google Scholar
• NODA K, SAGAGURI M, IDEISHI M, IKEDA M, ARAKAWAK: Cardioprotection by ACE inhibitors in ischemic hearts is independent of local angiotensin II formation. J. Hypertens. (1990) 8\(Suppl. 3):106–110.
   Google Scholar
• KIMURA E, HASHIMOTO K, FURAKAWA S, HAYAKAWA 5: Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am. HeartJ. (1973) 85:635–647.
   PubMed Web of Science ®Google Scholar
• BAUMGARTEN CR, LINZ W, KUNKEL G, SCHOLICENS BA, WIEMER G: Rarniprilat increases bradykinin outflow from isolated hearts of rat Br. J. Pharmacol. (1993) 108:293–295.
   Google Scholar
• CHAHINE RA, ADAM, A, YAMAGUCHI R et al.: Protectiveeffects of bradykinin on the ischemic heart implication of the Bc receptor. Br.J. Pharmacol. (1993) 108:318–322.
   PubMed Web of Science ®Google Scholar
• MARTORANA PA, KE1 ItNBACH B, BREIPOHL G, LINZ W,SCHOLICENS BA: Reduction of infarct size by local angiotensin converting enzyme inhibition is abolished by a bradykinin receptor antagonist. Eur. J. Pharmacol. (1990) 182:395–396.
   PubMed Web of Science ®Google Scholar
• ZUGHAIB ME, SUN J-Z, BOLLI R: Effect of angiotensin-converting enzyme inhibitors on myocardial ischae-mia/reperfusion injury: an overview. Basic Res. Cardiol. (1993) 88\(Suppl. 1):155–167.
   Google Scholar
• BENETOS A, GAVRAS H, STEWART JM et al.: Vasodepres-sor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension (1986) 8:971–974.
   PubMed Web of Science ®Google Scholar
• CARBONELL LF, CARRETERO OA, STEWART JM, SCICLI AG: Effect of a kinin antagonist on the acute antihyperten-sive activity of enaLaprilat in severe hypertension. Hy-pertension (1988) 11:239–243.
   PubMed Web of Science ®Google Scholar
• CARRETERO OA, MIYAZAKI S, SCICLI AG: Role of kinins In the acute antihypertensive effect of the converting enzyme inhibitor, captopriL Hypertension (1981) 3:18–22.
   Google Scholar
• PITT B: Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice. Cardiol-ogy (1995) 86\(Suppl. 1):41–45.
   Google Scholar
• WARD PE, BAUSBACK HE, ODYA CE: Kinin and angioten-sin metabolism by purified renal post-proline cleaving enzyme. Biochem. Pharmacol. (1987) 36:3187–3193.
   PubMed Web of Science ®Google Scholar
• REGOLI D, DRAPEAU G, ROVERO P et al.: Conversion of kinins and their antagonists into Bi receptor activators and blockers in isolated vessels. Eur.J. Pharmacol. (1986) 127:219–224.
   PubMed Web of Science ®Google Scholar
• ALMENOFF J, ORLOWSKI M: Membrane-bound kidneyneutral metalloendopeptidase: interactions with syn-thetic substrates, natural peptides, and inhibitors. Bio-chemistry (1983) 22:590–599.
   Google Scholar
• SCHRIEFER JA, MOLINEAUX CJ: Modulatory effect of endopeptidase inhibitors on bradykinin-induced con-traction of rat uterus. J. Pharmacol. Exp. Ther. (1993) 266:700–706.
   PubMed Web of Science ®Google Scholar
• PIEDIMONTE G, NADEL JA, LONG CS, HOFFMAN JI-E:Neutral endopeptidase in the heart Neutral endopepti-dase inhibition prevents isoproterenol-induced myo-cardial hypoperfusion in rats by reducing bradykinin degradation. Circ. Res. (1994) 75:770–779.
   PubMed Web of Science ®Google Scholar
• MAXWELL A, HUSSEIN' W, PIEDIMONTE G, HOFFMAN E: Effects of inhibiting neutral endopeptidase and kini-nase II on coronary and systemic hemodynamics in rats. Am.J. Physiol. (1995) 38:H1016–H1029.
   Google Scholar
• DANILEWICZ JC, BARCLAY PL, BARNISH IT et al.: UK-69, 578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem. Biophys. Res. Comm. (1989) 164:58–65.
   Google Scholar
• NORTHRIDGE D, ALABASTER C, CONNELL J et al.: Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet (1989) 11:591–593.
   Google Scholar
• BEVEN, E, CONNELL J, DOYLE J et al.: Candoxatril, aneutral endopeptidase inhibitor: efficacy and tolerabil-ity in essential hypertension.]. Hypertens. (1992) 10:607–613.
   PubMed Web of Science ®Google Scholar
• STERGIOU GS, HANNAH JA, BEVAN EG et al.: Combinedatriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J. Hyper-tens. (1994) 12:1310–1311.
   Google Scholar
• VEMULAPALLI S, CHIU PJS, WATKINS RW, FOSTER C, SYBERTZ EJ: Potentiation of ANF biological responses by SCH 42495 [N-[2(S)-(acetylthiomethyl)-3-(2-methyl-phenyl)-1-oxopropyl]-L-methionine ethylester, a neu- tral metalloendopeptidase (NEP) inhibitor in rats. Am. Hypertens. (1991) 4:15A–16A.
   Google Scholar
• RICHARDS AM, CROZIER IG, KOSOGLOU T et al.: En- dopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension (1993) 22:119–126.
   Google Scholar
• MARGULIES KB, CAVERO PG, SEYMOUR AA, DELANY NG, BENNET JC: Neutral endopeptidase inhibition potenti-ates the renal actions of atrial natriuretic factor. Kidney Int. (1990) 38:67–72.
   Google Scholar
• SEYMOUR AA, NORMAN JA, ASAAD MM et al.: Possible regulation of atrial natriuretic factor by neutral en-dopeptidase 24.11 and clearance receptors. J. Pharma-col. Exp. Then (1991) 256:1002–1009.
   Google Scholar
• SEYMOUR AA, ABBOA-OFFEI B, ASAAD MM, ROGERS WL: Evaluation of SQ28,603, an inhibitor of neutral en-dopeptidase, in conscious monkeys. Can. J. Physiol. Pharmacol. (1991) 69:1609–1617.
   PubMed Web of Science ®Google Scholar
• SEYMOUR AA, NORMAN JA, ASAAD MM etal.: Antihyper-tensive and renal activity of SQ28,603, an inhibitor of neutral endopeptidase. J. Cardiovasc. Pharmacol. (1991) 17:296–304.
   Google Scholar
• SEYMOUR AA, SHELDON JI-1, SMITH PL, ASSAD M, ROGERS WL: Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J. Pharmacol Exp. Ther. (1994) 269:263–270.
   Google Scholar
• ORLOWSKI M, MICHAUD C, MOLINEAUX CJ: Substrate-re-lated potent inhibitors of brain metalloendopeptidase. Biochemistry (1988) 27:597–602.
   PubMed Web of Science ®Google Scholar
• LASDUN A, REZNIK S, MOLINEAUX C, ORLOWSKI M: Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hor-mone. J. Pharmacol. Exp. Ther. (1989) 251:439–447.
   PubMed Web of Science ®Google Scholar
• CORDOZO C, ORLOWSKI M: Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropy1]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of en-dopeptidase 24.15, to N11,(R,S)-carboxy-3-phenyl-propylj-Ala-Ala is necessary for inhibition of angioten-sin converting enzyme. Peptides (1993) 14:1259–1262.
   Google Scholar
• WILLIAMS CH, YAMAMOTO T, WALSH DM, ALLSOP D: Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a po-tent inhibitor of angiotensin-converting enzyme. Biochem. J. (1993) 294:681–684.
   Google Scholar
• LEW R, EVANS R, LAKAT L et al.: Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo. Br. J. Pharmacol. (1996) 18:269–277.
   Google Scholar
• JIRÁCEK J, YIOTAKIS A, VINCENT B et al.: Development of highly potent and selective phosphinic peptide in-hibitors of zinc endopeptidase 24-15 using combinato-rial chemistry. J. Biol. Chem. (1995) 270:21701–21706.
   PubMed Web of Science ®Google Scholar
• PRECHEL MM, ORAWSKI AT, MAGGIORA LL, SIMMONS WH: Effect of a new aminopeptidase P inhibitor, ap-static', on bradykinin degradation in the rat lung. J Pharmacol. Exp. Ther. (1995) 275:1136–1142.
   PubMed Web of Science ®Google Scholar
• PHAM I, GONZALES W, DOUCET J et al.: Effects ofangiotensin-converting enzyme and neutral endopep-tidase inhibitors: influence of bradykinin. Eur. J. Phar-macol. (1996) 296:267–276.
   PubMed Web of Science ®Google Scholar
• SEYMOUR AA, ASAAD MM, LANOCE VM et al.: Systemichemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther. (1993) 266:872–883.
   Google Scholar
• TRIPPODO NC, FOX M, NATARAJAN V etal.: CombinedInhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart faihcre. J. Pharmacol. Exp. Ther. (1993) 267:108–116.
   Google Scholar
• TRIPPODO NC, PANCHAL BC, FOX M: Repression of angiotensin II and potentiation of bradykinin contrib-ute to the synergistic effects of dual metalloprotease Inhibition in heart failure. J. Pharmacol. Exp.Ther. (1995) 272:619–627.
   PubMed Web of Science ®Google Scholar
• LINZ W, SCHOLKENS BA, HAN YF: Beneficial effects of •the converting enzyme inhibitor, rarnapril, in ischemic rat hearts. J. Cardiovasc. Pharmacol. (1986) 10:S91-899. Early suggestion that some of the beneficial effects of ACE inhibitors are due to BK protection.
   Google Scholar
• FOURNIE-ZALUSKI M-C, CORIC P, TURCAUD S etal.: New dual inhibitors of neutral endopeptidase and angioten-sin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hy-pertension. J. Med. Chem. (1994) 37:1070–1083.
   Google Scholar
• FOURNIE-ZALUSKI M-C, CORIC P, THERY V etal.: Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. (1996) 39:2594–2608.
   Google Scholar
• FOURNIE-ZALUSKI M-C, GONZALES W, TURCAUD S etal.: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hyper-tension. Proc. Natl. Acad. Sci. USA (1994) 91:4072–4076.
   Google Scholar
• GONZALEZ VERA WG, FOURNIE-ZALUSKI M-C, PHAM I et al.: Hypotensive and natriuretic effects of RB 105, anew dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J. Pharma-col. Exp. Ther. (1995) 272:343–351.
   PubMed Web of Science ®Google Scholar
• GROS C, NOEL N, SOUQUE A et al.: Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, proper-ties, and potential cardiovascular applications of glyco-pril and alatriopriL Proc. Natl. Acad. Sci. USA (1991) 88:4210–4214.
   Google Scholar
• MARIE C, MOSSIAT C, LECOMTE J-M, SCHWARTZ JD, BRALET J: Hemodynatnic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J. Pharma-col. Exp. Ther. (1995) 275:1324–1331.
   PubMed Web of Science ®Google Scholar
• FLYNN GA, BEIGHT DW, MEHDI S etal.: Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. (1993) 36:2420–2423.
   Google Scholar
• FRENCH JF, FLYNN GA, GIROUX EL etal.: Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J. Pharmacol. Exp. Ther. (1994) 268:180–186.
   Google Scholar
• FRENCH JF, ANDERSON BA, DOWNS TR, DAGE RC: DualInhibition of angiotensin-converting enzyme and neu-tral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol. (1995) 26:107–113.
   PubMed Web of Science ®Google Scholar
• STANTON JL, SPERBECK DM, TRAPANI AJ et al.: Heterocy-clic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors. J. Med. Chem. (1993) 36:3829–3833.
   Google Scholar
• FINK CA, QIA0 Y, BERRY CJ et al.: New a-thiol dipeptidedual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.1. Med. Chem. (1995) 38:5023–5030.
   Google Scholar
• CHATELAIN RE, ODORICO LM, GHAI RD et al.: Antihyper-tensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin converting enzyme and neu-tral endopeptidase 24.11. FASE13 J. (1996) 10:A699.
   Google Scholar
• ROBL JA, SIMPKINS LM, STEVENSON J et al.: Dual metal-loprotease inhibitors. 1. Constrained peptidomknetics of mercaptoacyl dipeptides. Biomed. Chem. Lett. (1994) 4:1789–1794.
   Google Scholar
• ROBL JA, SIMPKINS LM, SULSKY R et al.: Dual metallopro-tease inhibitors. IL Effect of substitutional and stereo-chemistry on benzazepinone based mercaptoacetyls. Biomed. Chem. Lett. (1994) 4:1795–1800.
   Google Scholar
• ROBL JA, SUN C-Q, SIMPKINS LM et al.: Dual metallopro-tease inhibitors. HI. Utilization of bicyclic and monocy-clic diazepinone based mercaptoacetyls. Biomed. Chem. Lett. (1994) 4:2055–2060.
   Google Scholar
• TRIPPODO NC, ROBL JA, ASAAD MM et at: Cardiovasculareffects of the novel dual inhibitor of neutral endopep-tidase and angiotensin-converting enzyme BMS 182657 in experimental hypertension and heart failure. J. Phar-macol. Exp. Ther. (1995) 275:745–752.
   PubMed Web of Science ®Google Scholar
• SLUSARCHYK WA, ROBL JA, TAUNK PC et al.: Dual metal-loprotease inhibitors. V. Utilization of bicyclic azepi-nonethiavolidines and azepinonetetrahydrothiazines in constrained peptidomimetics of mercaptoacyl dipeptides. Bioorg. Med. Chem. Lett. (1995) 5:753–758.
   Google Scholar
• FARHY RD, HO KL, CARRETERO OA, SCICLI AG: ICinins mediate the antiproliferative effect of raniipril in rat carotid artery. Biochem. Biophys. Res. Commun. (1992) 182:283–288.
   PubMed Web of Science ®Google Scholar
• UNGER T, GOHLKE P, PAUL M, RETTIG R: Tissue renin-angiotensin system: fact or fiction? J. Cardiovasc. Phar-macol. (1991) 18\(Suppl. 2):S20–S25.
   Google Scholar
• PAUL M, BACHMANN J, GANTEN D: The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc. Med. (1992) 2:94–99.
   PubMed Web of Science ®Google Scholar
• DE GRAEFF PA, VAN GILST WH, WESSELING H: The cardiac renin-angiotensin system in different ischemic syndromes of the heart. In: The Cardiac-Renin Angioten-sin System. Lindpaintner K, Ganten D (Eds.), Futura Publish-ing Co., Armonk, NY (1994):201–231.
   Google Scholar
• HOOPER NM, HRYSZKO J, OPPONG SY, TURNER AJ: Inhibition by converting enzyme inhibitors of pig kid-ney atninopepticiase P. Hypertension (1992) 19:281–285.
   PubMed Web of Science ®Google Scholar